Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA

Acute promyelocytic leukemia (APL) is a lethal but potentially curable form of Acute myeloid leukemia (AML), and it responds better to chemotherapy than other forms of AML [1]. APL has a distinct genetic morphology compared with other acute leukemia. Specific chromosomal marker for APL is t(15; 17), with promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) oncogene activation. All-trans-retinoic acid (ATRA) in conjunction with an attenuated dose of chemotherapy (anthracyclines alone or in combination with other drugs) is the conventional and standard therapy for APL during remission induction and maintenance phase.

Source: Leukemia Research - January 29, 2018 Category: Hematology Authors: Ardeshir Ghavamzadeh, Mahdi Jalili, Sharbanoo Rostami, Marjan Yaghmaie, Leyla Sharifi Aliabadi, Seyed Asadollah Mousavi, Mohammad Vaezi, Hossein Kamranzadeh Fumani, Mohammad Jahani, Kamran Alimoghaddam Tags: Research paper Source Type: research